BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 27, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 27, 2007
View Archived Issues
Transient improvement in rheumatoid arthritis activity seen with CRx-139
Read More
Kiadis to provide Rhitol to physicians participating in phase I/II trial closed for enrollment
Read More
Artemisinin derivative shows promise in models of autoimmune inflammatory disease
Read More
Recent patents disclose new therapeutic options for neuropsychiatric disorders
Read More
New therapeutic agents for endocrine disorders disclosed in recent patents
Read More
Ardana reports positive preliminary results from phase II study of teverelix LA
Read More
Novel agents for allergic and respiratory disorders described in recent Boehringer Ingelheim patent
Read More
Preclinical studies of arthritis therapy target TNF-alpha and Bcl-2
Read More
Selective and multitargeted B-Raf inhibitors described at Deciphera
Read More
Selective LMP7 proteasome inhibitor shows antirheumatic activity in vivo
Read More
P2X7 receptor blockade is associated with reduced joint destruction in inflammatory arthritis
Read More
Modulation of 5-HT2 signaling shows benefit in models of inflammatory arthritis
Read More
European Commission approves Wyeth Pharmaceuticals' Torisel for renal cell carcinoma
Read More
MedImmune initiates phase I clinical trial of CAM-3001 for rheumatoid arthritis
Read More
Roche and Maxygen terminate development of MAXY-alpha
Read More
Merck & Co. files marketing authorization application with EMEA for vorinostat
Read More
LEO Pharma launches ATryn for hereditary antithrombin deficiency
Read More
FDA removes hold on Targeted Genetics' phase I/II clinical trial of tgAAC-94
Read More
Sygnis and Dr. Reddy's enter 10-year supply agreement for AX-200 for stroke
Read More
Daval International gets MHRA approval for phase IIb trial of Aimspro for MS
Read More
Mercury develops protein-kinase technology for treatment of type 2 diabetes
Read More
VioQuest initiates phase IIa study of Lenocta for the treatment of solid tumors
Read More
